 vitro activity tosufloxacin new quinolone respiratory pathogens cystic fibrosis sputum microdilution methods vitro activity tosufloxacin new quinolone agents quinolones diverse cystic fibrosis sputum isolates cystic fibrosis centers United Pseudomonas aeruginosa conventional resistant ceftazidime aztreonam gentamicin and/or tobramycin Escherichia coli Pseudomonas cepacia Staphylococcus Haemophilus influenzae Tosufloxacin MICs isolates standard aeruginosa mg/liter resistant aeruginosa mg/liter coli equal mg/liter cepacia mg/liter mg/liter influenzae equal mg/liter Tosufloxacin activities standard resistant strains aeruginosa similar comparative quinolones Against coli tosufloxacin activity similar quinolones Against aureus tosufloxacin activity similar trimethoprim-sulfamethoxazole cephalexin tosufloxacin active agents Against influenzae tosufloxacin activity similar quinolones minor diminution activity pH major diminution activity pH inoculum sizes equal CFU/ml Activity sputum serum omission cation supplementation Tosufloxacin consistent activity common cystic fibrosis pathogens high degree activity aureus activity aeruginosa gram-negative bacteria interest vitro studies assessment activity vivo models cystic fibrosis pulmonary infections